nemolizumab (Nemluvio)

following a full submission:

nemolizumab (Nemluvio®) is accepted for restricted use within NHSScotland.

Indication under review: for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors in adults and adolescents 12 years and older with a body weight of at least 30 kg, who are candidates for systemic therapy.

SMC restriction: for use in patients who have had an inadequate response to an existing systemic immunosuppressant such as ciclosporin, or in whom such treatment is considered unsuitable and where a biologic would otherwise be offered.

Three phase III studies demonstrated superiority of nemolizumab in improving signs and symptoms of atopic dermatitis when compared with placebo, in combination with topical corticosteroids with or without topical calcineurin inhibitors, in patients with moderate-to-severe dermatitis.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.